The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Endocrinology

• Publication date

  2008-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1210/en.2008-0817PMID 18703623
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Symptoms in the Menopausal Transition: Hormone and Behavioral Correlates

  2008cited by this paper
• The future of the new selective estrogen receptor modulators

  2007cited by this paper
• The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety

  2007cited by this paper
• Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy.

  2007cited by this paper
• Low‐dose hormone therapy in the perimenopause

  2007cited by this paper
• Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society

  2006cited by this paper
• Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity.

  2006cited by this paper
• Estrogen receptor modulator review

  2006cited by this paper
• Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.

  2005cited by this paper
• Endometrial Effects of Bazedoxifene Acetate, a Novel Selective Estrogen Receptor Modulator, in Postmenopausal Women

  2005cited by this paper
• Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity.

  2005cited by this paper
• Recent advances in estrogen receptor modulators.

  2005cited by this paper
• Hormone Replacement Therapy, Selective Estrogen Receptor Modulators, and Tissue-Specific Compounds

  2004cited by this paper
• Postmenopausal osteoporosis and hormone replacement therapy.

  2004cited by this paper
• Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats.

  2004cited by this paper
• Molecular Mechanisms, Physiological Consequences and Pharmacological Implications of Estrogen Receptor Action

  2004cited by this paper
• National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section

  2004cited by this paper
• Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.

  2003cited by this paper
• Estrogens in postmenopausal women: recent insights.

  2003cited by this paper
• Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results.

  2003cited by this paper
• Advances in the science of estrogen receptor modulation.

  2003cited by this paper
• Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta.

  2003cited by this paper
• Estrogen: physiology, pharmacology, and formulations for replacement therapy.

  2002cited by this paper
• Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators.

  2002cited by this paper
• Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens.

  2001cited by this paper
• Developing a SERM: Stringent Preclinical Selection Criteria Leading to an Acceptable Candidate (WAY‐140424) for Clinical Evaluation

  2001cited by this paper
• How many women lose bone mineral density while taking hormone replacement therapy? Results from the Postmenopausal Estrogen/Progestin Interventions Trial.

  2000cited by this paper
• Diagnosis and treatment of atrophic vaginitis.

  2000cited by this paper
• Identification of Selective Estrogen Receptor Modulators by Their Gene Expression Fingerprints*

  2000cited by this paper
• Recent insights into the varying activity of estrogens.

  2000cited by this paper
• The effect of estrogens and antiestrogens in a rat model for hot flush.

  1998cited by this paper
• Symptom Relief and Side Effects of Postmenopausal Hormones: Results From the Postmenopausal Estrogen/Progestin Interventions Trial

  1998cited by this paper
• Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions.

  1998cited by this paper
• The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen.

  1998cited by this paper
• Nuclear receptor coactivators.

  1997cited by this paper
• The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women.

  1997cited by this paper
• Characterization of the ovariectomized rat model for the evaluation of estrogen effects on plasma cholesterol levels.

  1997cited by this paper
• The endocrinology of the menopause.

  1996cited by this paper
• Treatment of the Postmenopausal Woman: Basic and Clinical Aspects

  1994cited by this paper
• Effects of long-term estrogen replacement therapy. II. Neoplasia.

  1979cited by this paper
• Association of exogenous estrogen and endometrial carcinoma.

  1975cited by this paper

• The effect of estradiol and selective estrogen receptor modulators on lipid profile in the ovariectomized rat model

  2025cites this paper
• Selective steroid receptor modulators, degraders and PROTACs: Therapeutic strategies in management of endocrine-related cancers.

  2025cites this paper
• SERMs revisited: Can they improve menopausal care?

  2022cites this paper
• A Preliminary Study on the Effects of Black Cohosh Preparations on Bone Metabolism of Rat Models With GnRH-a-Induced Peri-Menopausal Symptoms

  2022cites this paper
• Anti-fibrotic effect of a selective estrogen receptor modulator in systemic sclerosis

  2022cites this paper
• Phytoestrogens as estrogen receptor ligands

  2022cites this paper
• Sex Hormones in Lymphedema

  2021cites this paper
• Selective estrogen receptor modulators and bone health

  2021cites this paper
• [Efficacy of black cohosh extracts for improving low estrogen status induced by postoperative GnRHa treatment in patients with endometriosis: a systematic review].

  2020cites this paper
• Effect of conjugated estrogens and bazedoxifene on glucose, energy and lipid metabolism in obese postmenopausal women.

  2020cites this paper
• Selective Estrogen Receptor Modulators (SERMs) and Menopausal Hormone Therapy (MHT)

  2020cites this paper
• Tissue selective effects of bazedoxifene on the musculoskeletal system in female mice.

  2020cites this paper
• Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer

  2019cites this paper
• Repurposing of drugs as STAT3 inhibitors for cancer therapy.

  2019cites this paper
• Auf gutem Weg durch die Wechseljahre

  2019cites this paper
• Effects of bazedoxifene and low-intensity aerobic exercise on bone and fat parameters in ovariectomized rats

  2019cites this paper
• Conjugated Estrogens and Bazedoxifene Improve β Cell Function in Obese Menopausal Women

  2019cites this paper
• Estrogens Promote Misfolded Proinsulin Degradation to Protect Insulin Production and Delay Diabetes.

  2018cites this paper
• What do TSECs provide in the menopausal hormone therapy?

  2018cites this paper
• Hormone Therapy and Breast Cancer: Emerging Steroid Receptor Mechanisms.

  2018cites this paper
• Tissue selective estrogen complex (TSEC): a review

  2018cites this paper
• A Novel Strategy to Improve Women’s Health: Selective Estrogen Receptor Modulators

  2018cites this paper
• A comprehensive overview on osteoporosis and its risk factors

  2018cites this paper
• Vaginal bleeding/spotting with conjugated estrogens/bazedoxifene, conjugated estrogens/medroxyprogesterone acetate, and placebo

  2018cites this paper
• Heat Shock Protein 72 Regulation of Metabolism

  2018cites this paper
• Announces FDA Approval of DUAVEE TM ( conjugated estrogens / bazedoxifene ) for the Treatment of Moderate-to-Severe Vasomotor Symptoms ( Hot Flashes ) Associated with Menopause and the Prevention of Postmenopausal Osteoporosis [ 1 ]

  2018cites this paper
• Preclinical breast effects of a tissue selective estrogen complex (TSEC) including conjugated estrogen with bazedoxifene.

  2017cites this paper
• The Tissue-Selective Estrogen Complex (Bazedoxifene/Conjugated Estrogens) for the Treatment of Menopause

  2017influential citation
• The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms

  2017cites this paper
• Hormone Therapy (II): Tibolone, The TSEC Concept

  2017cites this paper
• Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy

  2017cites this paper
• EFFECT OF ESTRADIOL, IMIPRAMINE AND FLUOXETINE ON BRAIN SEROTONIN LEVELS IN OVARIECTOMIZED-INDUCED OSTEOPOROTIC RATS

  2017cites this paper
• The combination of conjugated equine estrogens with bazedoxifene prevents streptozotocin-induced diabetes in female mice

  2016cites this paper
• Conjugated estrogens and bazedoxifene in minority populations: pooled analysis of four phase 3 trials

  2016cites this paper
• Differential utilization of nuclear and extranuclear receptor signaling pathways in the actions of estrogens, SERMs, and a tissue-selective estrogen complex (TSEC).

  2016cites this paper
• Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials

  2016influential citation
• Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials

  2016cites this paper
• Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy

  2016cites this paper
• GPER-novel membrane oestrogen receptor.

  2016cites this paper
• Patient considerations in the management of menopausal symptoms: role of conjugated estrogens with bazedoxifene

  2016cites this paper
• Differential effects of selective estrogen receptor modulators on the vagina and its supportive tissues

  2016cites this paper
• The effect of conjugated estrogens/bazedoxifene therapy on body weight of postmenopausal women: pooled analysis of five randomized, placebo-controlled trials

  2015cites this paper
• Retraction: Protective effects of bazedoxifene paired with conjugated estrogens on pancreatic β-cell dysfunction.

  2015cites this paper
• Effects of genistein in combination with conjugated estrogens on endometrial hyperplasia and metabolic dysfunction in ovariectomized mice.

  2015cites this paper
• Emerging hormonal treatments for menopausal symptoms

  2015cites this paper
• A Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Lipid Parameters in Postmenopausal Women From the Selective Estrogens, Menopause, and Response to Therapy (SMART) Trials.

  2015cites this paper
• Prostaglandin Dependent Control of an Endogenous Estrogen Receptor Agonist by Osteoblasts

  2015cites this paper
• Bazedoxifene/conjugated estrogens combination for the treatment of the vasomotor symptoms associated with menopause and for prevention of osteoporosis in postmenopausal women.

  2015cites this paper
• Effects of conjugated estrogens/bazedoxifene on lipid and coagulation variables: a randomized placebo- and active-controlled trial

  2015cites this paper
• Novel ligands balance estrogen receptor β and α agonism for safe and effective suppression of the vasomotor response in the ovariectomized female rat model of menopause.

  2014cites this paper
• Osteoporosis in the at‐risk asthmatic

  2014cites this paper
• Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy

  2014cites this paper
• Tissue-selective estrogen complexes with bazedoxifene prevent metabolic dysfunction in female mice.

  2014cites this paper
• Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms.

  2014cites this paper
• Endometriosis impairs bone marrow-derived stem cell recruitment to the uterus whereas bazedoxifene treatment leads to endometriosis regression and improved uterine stem cell engraftment.

  2014cites this paper
• Conjugated Estrogen/Bazedoxifene Tablets for the Treatment of Moderate-to-Severe Vasomotor Symptoms Associated with Menopause

  2014cites this paper
• Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan

  2014cites this paper
• Selective estrogen receptor modulators: tissue specificity and clinical utility

  2014cites this paper
• Selective estrogen receptor modulators: tissue specificity and clinical utility

  2014cites this paper
• Differential effects of menopausal therapies on the endometrium

  2014influential citation
• Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss.

  2014cites this paper
• An overview of current and emerging SERMs.

  2014cites this paper
• Current and evolving approaches to individualizing estrogen receptor-based therapy for menopausal women.

  2014cites this paper
• Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes

  2014cites this paper
• Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause

  2013cites this paper
• Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture

  2013cites this paper
• Tissue Selective Estrogen Complexes (TSECs) Differentially Modulate Markers of Proliferation and Differentiation in Endometrial Cells

  2013cites this paper
• Tissue-selective estrogen complexes for postmenopausal women.

  2013cites this paper
• Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women

  2013cites this paper
• Pharmacokinetic evaluation of bazedoxifene for the treatment of osteoporosis

  2013influential citation
• Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women

  2013cites this paper
• Nuclear Receptors and Their Selective Pharmacologic Modulators

  2013cites this paper
• Inhibitory effects of a bazedoxifene/conjugated equine estrogen combination on human breast cancer cells in vitro.

  2013cites this paper
• Evolution of the tissue selective estrogen complex (TSEC)

  2013influential citation
• Global Profiling of TSEC Proliferative Potential by the Use of a Reporter Mouse for Proliferation

  2013cites this paper
• The Legacy of Tamoxifen

  2013cites this paper
• Management of Estrogen Deficiency

  2013cites this paper
• The role of estrogens in control of energy balance and glucose homeostasis.

  2013cites this paper
• Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model

  2013cites this paper
• Differentiation in Endometrial Cells Tissue Selective Estrogen Complexes ( TSECs ) Differentially Modulate Markers of Proliferation and

  2012cites this paper
• Recommendations on the management of fragility fracture risk in women younger than 70 years

  2012cites this paper
• Using bazedoxifene plus conjugated estrogens for treating postmenopausal women: a comprehensive review

  2012cites this paper
• The Tissue Selective Estrogen Complex: A Promising New Menopausal Therapy

  2012cites this paper
• The Tissue Selective Estrogen Complex: A Novel Approach to the Treatment of Menopausal Symptoms

  2012cites this paper
• Pharmacological Treatment of Osteoporosis

  2012cites this paper
• Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens

  2012cites this paper
• The evolution of selective estrogen receptor modulators in osteoporosis therapy

  2012cites this paper
• Importance of oestrogen receptors to preserve functional β-cell mass in diabetes

  2012cites this paper
• Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention

  2012cites this paper
• Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy

  2012cites this paper
• Raloxifene for the treatment of postmenopausal osteoporosis

  2012cites this paper
• Recent Developments in Pharmacotherapy for Vasomotor Symptoms

  2012cites this paper
• The Tissue-Selective Estrogen Complex (TSEC): A Promising New Therapy for Menopausal Symptoms and Postmenopausal Osteoporosis

  2012cites this paper
• Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats.

  2011influential citation
• Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model.

  2011cites this paper
• The conundrum of estrogen receptor oscillatory activity in the search for an appropriate hormone replacement therapy.

  2011influential citation
• S-equol and the fermented soy product SE5-OH containing S-equol similarly decrease ovariectomy-induced increase in rat tail skin temperature in an animal model of hot flushes

  2011cites this paper
• Preventing osteoporosis in symptomatic postmenopausal women

  2011cites this paper
• Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE)

  2011cites this paper
• Current treatment options for vulvovaginal atrophy

  2011cites this paper